The BEAUTIFUL study:: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction baseline characteristics of the study population

被引：43

作者：

Fox, Kim ^{[1
]}

Recena, J. Balaguer ^{[1
]}

Garcia-Aranda, V. Lopez ^{[1
]}

Valderrama, J. Caparros ^{[1
]}

Alonso, L. F. Iglesias ^{[1
]}

Calvar, A. San Roman ^{[1
]}

Aviles, F. Fernandez ^{[1
]}

Villa, F. Perez ^{[1
]}

Cortada, J. Bruguera ^{[1
]}

Alvarez, R. Fernandez ^{[1
]}

Peiro, F. Noriega ^{[1
]}

Iglesias, F. Calvo ^{[1
]}

Toral, B. Sevilla ^{[1
]}

Bescos, L. Lopez ^{[1
]}

De Burgos, F. Garcia ^{[1
]}

Casado, R. Sola ^{[1
]}

Galve, E. ^{[1
]}

Garcia, G. Casares ^{[1
]}

Dellborg, M. ^{[1
]}

Herlitz, J. ^{[1
]}

Ullman, B. ^{[1
]}

Blomgren, J. ^{[1
]}

Bandh, S. ^{[1
]}

Oehlin, H. ^{[1
]}

Dubach, P. ^{[1
]}

Gallino, A. ^{[1
]}

Hess, O. ^{[1
]}

Moccetti, T. ^{[1
]}

Eeckhout, E. ^{[1
]}

Vontobel, H. ^{[1
]}

Delabays, A. ^{[1
]}

Erol, K. ^{[1
]}

Kozan, O. ^{[1
]}

Mutlu, B. ^{[1
]}

Ergene, O. ^{[1
]}

Acarturk, E. ^{[1
]}

Yilmaz, H. ^{[1
]}

Ural, D. ^{[1
]}

Parkhomenko, O. ^{[1
]}

Polyvoda, S. ^{[1
]}

Dyadyk, A. ^{[1
]}

Vatutin, M. ^{[1
]}

Karpenko, O. ^{[1
]}

Kubyshkin, V. ^{[1
]}

Rudenko, L. ^{[1
]}

Putintsev, V. ^{[1
]}

Krayz, I. ^{[1
]}

Kovalsky, I. ^{[1
]}

Rudyk, Y. ^{[1
]}

Yurlov, V. ^{[1
]}

机构：

[1] Royal Brompton Hosp, London SW3 6NP, England

来源：

CARDIOLOGY | 2008年 / 110卷 / 04期

关键词：

coronary artery disease; heart rate; ivabradine; left ventricular dysfunction; mortality;

D O I：

10.1159/000112412

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current I-f in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline. Methods: BEAUTIFUL is an international, multicentre, randomized, double-blind trial to compare ivabradine with placebo in reducing mortality and cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction (ejection fraction < 40%). Results: A total of 10,917 patients were randomized. At baseline, their mean age was 65 years, 83% were male, 98% Caucasian, 88% had previous myocardial infarction, 37% had diabetes, and 40% had metabolic syndrome. Mean ejection fraction was 32% and resting heart rate was 71.6 bpm. Concomitant medications included beta-blockers (87%), renin-angiotensin system agents (89%), antithrombotic agents (94%), and lipid-lowering agents (76%). Conclusions: Main results from BEAUTIFUL are expected in 2008, and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients. Copyright (c) 2007 S. Karger AG, Basel.

引用

页码：271 / 282

页数：12

共 69 条

[41] The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe Part 2: treatment
Komajda, M
Swedberg, K
Cleland, J
Aguilar, JC
Cohen-Solal, A
Dietz, R
Gavazzi, A
Van Gilst, WH
Hobbs, R
Madeira, HC
Moiseyev, VS
Preda, I
Widimsky, J
Freemanthle, N
Eastaugh, J
Mason, J
[J]. EUROPEAN HEART JOURNAL, 2003, 24 (05) : 464 - 474
[42] National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance
Kramer, Judith M.
Hammill, Bradley
Anstrom, Kevin J.
Fetterolf, Donald
Snyder, Richard
Charde, John P.
Hoffman, Barbara S.
LaPointe, Nancy Allen
Peterson, Eric
[J]. AMERICAN HEART JOURNAL, 2006, 152 (03) : 454 - +
[43] Intensive lipid lowering with atorvastatin in patients with stable coronary disease
LaRosa, JC
Grundy, SM
Waters, DD
Shear, C
Barter, P
Fruchart, J
Gotto, AM
Greten, H
Kastelein, JJP
Shepherd, J
Wenger, NK
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) : 1425 - 1435
[44] Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBISII trial
Lechat, P
Hulot, JS
Escolano, S
Mallet, A
Leizorovicz, A
Werhlen-Grandjean, M
Pochmalicki, G
Dargie, H
[J]. CIRCULATION, 2001, 103 (10) : 1428 - 1433
[45] Risk-treatment mismatch in the pharmacotherapy of heart failure
Lee, DS
Tu, JV
Juurlink, DN
Alter, DA
Ko, DT
Austin, PC
Chong, A
Stukel, TA
Levy, D
Laupacis, A
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (10): : 1240 - 1247
[46] Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure
Lenzen, MJ
Boersma, E
Scholte op Reimer, WJM
Balk, AHMM
Komajda, M
Swedberg, K
Follath, F
Jimenez-Navarro, M
Simoons, ML
Cleland, JGF
[J]. EUROPEAN HEART JOURNAL, 2005, 26 (24) : 2706 - 2713
[47] Expert consensus document on β-adrenergic receptor blockers
López-Sendón, J
Swedberg, K
McMurray, J
Tamargo, J
Maggioni, AP
Dargie, H
Tendera, M
Waagstein, F
Kjekshus, J
Lechat, P
Torp-Pedersen, C
[J]. EUROPEAN HEART JOURNAL, 2004, 25 (15) : 1341 - 1362
[48] A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction
Manz, M
Reuter, M
Lauck, G
Omran, H
Jung, W
[J]. CARDIOLOGY, 2003, 100 (03) : 149 - 155
[49] Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations - GISSI-Prevenzione mortality risk chart
Marchioli, R
Avanzini, F
Barzi, F
Chieffo, C
Di Castelnuovo, A
Franzosi, MG
Geraci, E
Maggioni, AP
Marfisi, RM
Mininni, N
Nicolosi, GL
Santini, M
Schweiger, C
Tavazzi, L
Tognoni, G
Valagussa, F
[J]. EUROPEAN HEART JOURNAL, 2001, 22 (22) : 2085 - 2103
[50] Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure:: baseline characteristics of patients in the Candesartan in Heart failure -: Assessment of Reduction in Mortality and morbidity (CHARM) programme
McMurray, J
Östergren, J
Pfeffer, M
Swedberg, K
Granger, C
Yusuf, S
Held, P
Michelson, E
Olofsson, B
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (03) : 261 - 270

← 1 2 3 4 5 6 7 →